In this issue:
Lobectomy vs sublobar resection in STAS+ T1 lung adenocarcinoma
Adjuvant erlotinib in resected EGFR-mutant NSCLC
Updated data from KEYNOTE-024
Nivolumab in pretreated NSCLC harbouring KRAS mutations
FLAURA trial post-progression outcomes
Encouraging data from CHEST Australia
TMB and EGFR-TKIs in EGFR-mutant lung cancers
Pyrotinib shows antitumour activity in HER2 exon 20 mutant NSCLC
Nivolumab ± ipilimumab in relapsed malignant pleural mesothelioma
Clonal MET amplification and TKI resistance in EGFR-mutant NSCLC
Please login below to download this issue (PDF)